Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy IN8bio IncCommon Stock stock | $6.65

Learn how to easily invest in IN8bio IncCommon Stock stock.

IN8bio Inc. Common Stock
+ $0.05 ( + 0.75%)

IN8bio Inc. Common Stock is a biotechnology business based in the US. IN8bio IncCommon Stock shares (INAB) are listed on the NASDAQ and all prices are listed in US Dollars. IN8bio IncCommon Stock employs 13 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in IN8bio IncCommon Stock

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – INAB – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

IN8bio IncCommon Stock stock price (NASDAQ: INAB)

Use our graph to track the performance of INAB stocks over time.

IN8bio IncCommon Stock shares at a glance

Information last updated 2021-10-24.
Latest market close$6.65
52-week range$5.76 - $10.32
50-day moving average $7.13
200-day moving average $7.77
Wall St. target price$15.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.34

Buy IN8bio IncCommon Stock shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy IN8bio IncCommon Stock stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

IN8bio IncCommon Stock price performance over time

Historical closes compared with the close of $6.65 from 2021-10-25

1 week (2021-10-19) 12.33%
1 month (2021-09-24) -12.50%
3 months (2021-07-22) N/A
6 months (2021-04-22) N/A
1 year (2020-10-22) N/A
2 years (2019-10-22) N/A
3 years (2018-10-22) N/A
5 years (2016-10-22) N/A

IN8bio IncCommon Stock financials

Gross profit TTM $0
Return on assets TTM -55.43%
Return on equity TTM -122.74%
Profit margin 0%
Book value N/A
Market capitalisation $124.9 million

TTM: trailing 12 months

Shorting IN8bio IncCommon Stock shares

There are currently 37,687 IN8bio IncCommon Stock shares held short by investors – that's known as IN8bio IncCommon Stock's "short interest". This figure is 337.7% up from 8,611 last month.

There are a few different ways that this level of interest in shorting IN8bio IncCommon Stock shares can be evaluated.

IN8bio IncCommon Stock's "short interest ratio" (SIR)

IN8bio IncCommon Stock's "short interest ratio" (SIR) is the quantity of IN8bio IncCommon Stock shares currently shorted divided by the average quantity of IN8bio IncCommon Stock shares traded daily (recently around 30890.983606557). IN8bio IncCommon Stock's SIR currently stands at 1.22. In other words for every 100,000 IN8bio IncCommon Stock shares traded daily on the market, roughly 1220 shares are currently held short.

To gain some more context, you can compare IN8bio IncCommon Stock's short interest ratio against those of similar companies.

However IN8bio IncCommon Stock's short interest can also be evaluated against the total number of IN8bio IncCommon Stock shares, or, against the total number of tradable IN8bio IncCommon Stock shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case IN8bio IncCommon Stock's short interest could be expressed as 0% of the outstanding shares (for every 100,000 IN8bio IncCommon Stock shares in existence, roughly 0 shares are currently held short) or 0.0138% of the tradable shares (for every 100,000 tradable IN8bio IncCommon Stock shares, roughly 14 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against IN8bio IncCommon Stock.

Find out more about how you can short IN8bio IncCommon Stock stock.

IN8bio IncCommon Stock share dividends

We're not expecting IN8bio IncCommon Stock to pay a dividend over the next 12 months.

IN8bio IncCommon Stock overview

IN8bio, Inc. , a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. The company develops INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020.

Frequently asked questions

What percentage of IN8bio IncCommon Stock is owned by insiders or institutions?
Currently 15.173% of IN8bio IncCommon Stock shares are held by insiders and 35.961% by institutions.
How many people work for IN8bio IncCommon Stock?
Latest data suggests 13 work at IN8bio IncCommon Stock.
When does the fiscal year end for IN8bio IncCommon Stock?
IN8bio IncCommon Stock's fiscal year ends in December.
Where is IN8bio IncCommon Stock based?
IN8bio IncCommon Stock's address is: 79 Madison Avenue, New York, NY, United States, 10016
What is IN8bio IncCommon Stock's ISIN number?
IN8bio IncCommon Stock's international securities identification number is: US45674E1091

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site